BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 56 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,846 | -1.2% | 10,150,000 | 0.0% | 0.02% | 0.0% |
| Q2 2023 | $9,970 | -16.6% | 10,150,000 | -12.9% | 0.02% | -20.7% |
| Q1 2023 | $11,953 | -3.3% | 11,650,000 | 0.0% | 0.03% | -9.4% |
| Q4 2022 | $12,364 | -99.9% | 11,650,000 | 0.0% | 0.03% | 0.0% |
| Q3 2022 | $11,543,000 | +1.4% | 11,650,000 | +1.3% | 0.03% | +6.7% |
| Q2 2022 | $11,385,000 | -12.4% | 11,500,000 | -11.5% | 0.03% | +20.0% |
| Q1 2022 | $12,994,000 | -4.4% | 13,000,000 | 0.0% | 0.02% | -3.8% |
| Q4 2021 | $13,593,000 | +1.9% | 13,000,000 | 0.0% | 0.03% | -3.7% |
| Q3 2021 | $13,341,000 | – | 13,000,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wellesley Asset Management | 53,670 | $57,726,000 | 3.34% |
| SHENKMAN CAPITAL MANAGEMENT INC | 26,959,000 | $29,149,000 | 3.04% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 84,134,000 | $90,539,000 | 1.93% |
| Cheyne Capital Management (UK) LLP | 3,220,000 | $3,452,000 | 1.75% |
| PFM Health Sciences, LP | 40,300,000 | $43,210,000 | 1.52% |
| Sonora Investment Management, LLC | 6,370,000 | $6,807,000 | 0.56% |
| MACKAY SHIELDS LLC | 66,018,000 | $70,980,000 | 0.49% |
| ZAZOVE ASSOCIATES LLC | 1,500,000 | $1,608,000 | 0.20% |
| IRON Financial LLC | 275,000 | $295,000 | 0.15% |
| PALISADE CAPITAL MANAGEMENT, LP | 3,000,000 | $3,216,000 | 0.08% |